APO Research
Talk to an analyst

APO RESEARCH · REPORT

Peptide Cancer Vaccine

Cancer peptide vaccination, as an immunotherapeutic approach against solid tumors, is currently employed in several clinical research protocols. The underlying mechanism of peptide-based vaccines involves the generation of a T-cell immune response against tumor or enhancement of an endogenous antitumor immunity pre-existing in the host.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Cancer peptide vaccination, as an immunotherapeutic approach against solid tumors, is currently employed in several clinical research protocols. The underlying mechanism of peptide-based vaccines involves the generation of a T-cell immune response against tumor or enhancement of an endogenous antitumor immunity pre-existing in the host.

Selected research

Market Outlook & Growth Opportunities

Global Peptide Cancer Vaccine Market Outlook and Growth Opportunities 2026

2 January 2026197 pages

Choose your research edition.

Industry ResearchPeptide Cancer Vaccine Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Peptide Cancer Vaccine Industry Growth and Trends Forecast to 2032107 pages · $3,450 USDMarket StructureGlobal Peptide Cancer Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Peptide Cancer Vaccine Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Peptide Cancer Vaccine Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

Cancer peptide vaccination, as an immunotherapeutic approach against solid tumors, is currently employed in several clinical research protocols. The underlying mechanism of peptide-based vaccines involves the generation of a T-cell immune response against tumor or enhancement of an endogenous antitumor immunity pre-existing in the host.

Peptide Cancer Vaccine can be used for Breast Cancer, Lung Cancer, Melanoma, Prostate Cancer and Others cancers. The most proportion research of Peptide Cancer Vaccine is about Melanoma, and the proportion is about 40%.

USA is the largest consumption place, with a consumption market share nearly 53% . Following USA, Europe is the second largest consumption place with the consumption market share of 31%.

Read the full market overview

Boston Biomedical, Ultimovacs, BrightPath Biotherapeutics, TapImmune, Immatics, Sellas, Imugene, VAXON Biotech, Generex Biotechnology, ISA Pharmaceuticals and OncoTherapy Science are the key manufacturters of Peptide Cancer Vaccine.

This report provides an overview of the global Peptide Cancer Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Peptide Cancer Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Peptide Cancer Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Peptide Cancer Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Peptide Cancer Vaccine Segment by Company

Boston Biomedical

Ultimovacs

BrightPath Biotherapeutics

TapImmune

Immatics

Sellas

Imugene

VAXON Biotech

Generex Biotechnology

ISA Pharmaceuticals

OncoTherapy Science

Peptide Cancer Vaccine Segment by Pipeline

ITK-1

GRN-1201

TPIV200

TPIV110

UV1

Galinpepimut-S

TARP 27-35

HER-Vaxx

Vx-001

Others

Peptide Cancer Vaccine Segment by Application

Breast Cancer

Lung Cancer

Melanoma

Prostate Cancer

Others

Peptide Cancer Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Peptide Cancer Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Peptide Cancer Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Peptide Cancer Vaccine significant trends, drivers, influence factors in global and regions.

6. To analyze Peptide Cancer Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peptide Cancer Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Peptide Cancer Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peptide Cancer Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Peptide Cancer Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Peptide Cancer Vaccine industry.

Chapter 3: Detailed analysis of Peptide Cancer Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Peptide Cancer Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Peptide Cancer Vaccine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Peptide Cancer Vaccine Industry Trends Table 2. Peptide Cancer Vaccine Industry Drivers Table 3. Peptide Cancer Vaccine Industry Opportunities and Challenges Table 4. Peptide Cancer Vaccine Industry Restraints Table 5. Global Peptide Cancer Vaccine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Peptide Cancer Vaccine Revenue Share by Company (2021-2026) Table 7. Global Peptide Cancer Vaccine Sales Volume by Company (K Doses) & (2021-2026) Table 8. Global Peptide Cancer Vaccine Sales Volume Share by Company (2021-2026) Table 9. Global Peptide Cancer Vaccine Average Price (USD/Dose) of Company (2021-2026) Table 10. Global Peptide Cancer Vaccine Company Ranking, (2024-2026) & (USD Million) Table 11. Global Peptide Cancer Vaccine Key Company Manufacturing Base & Headquarters Table 12. Global Peptide Cancer Vaccine Company, Product Type & Application Table 13. Global Peptide Cancer Vaccine Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Peptide Cancer Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of ITK-1 Table 18. Significant Companies of GRN-1201 Table 19. Significant Companies of TPIV200 Table 20. Significant Companies of TPIV110 Table 21. Significant Companies of UV1 Table 22. Significant Companies of Galinpepimut-S Table 23. Significant Companies of TARP 27-35 Table 24. Significant Companies of HER-Vaxx Table 25. Significant Companies of Vx-001 Table 26. Significant Companies of Others Table 27. Global Peptide Cancer Vaccine Sales Volume by Type 2021 VS 2025 VS 2032 (K Doses) Table 28. Global Peptide Cancer Vaccine Sales Volume by Type (2021-2026) & (K Doses) Table 29. Global Peptide Cancer Vaccine Sales Volume by Type (2027-2032) & (K Doses) Table 30. Global Peptide Cancer Vaccine Sales Volume Share by Type (2021-2026) Table 31. Global Peptide Cancer Vaccine Sales Volume Share by Type (2027-2032) Table 32. Global Peptide Cancer Vaccine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Peptide Cancer Vaccine Sales Value by Type (2021-2026) & (US$ Million) Table 34. Global Peptide Cancer Vaccine Sales Value by Type (2027-2032) & (US$ Million) Table 35. Global Peptide Cancer Vaccine Sales Value Share by Type (2021-2026) Table 36. Global Peptide Cancer Vaccine Sales Value Share by Type (2027-2032) Table 37. Significant Companies of Breast Cancer Table 38. Significant Companies of Lung Cancer Table 39. Significant Companies of Melanoma Table 40. Significant Companies of Prostate Cancer Table 41. Significant Companies of Others Table 42. Global Peptide Cancer Vaccine Sales Volume by Application 2021 VS 2025 VS 2032 (K Doses) Table 43. Global Peptide Cancer Vaccine Sales Volume by Application (2021-2026) & (K Doses) Table 44. Global Peptide Cancer Vaccine Sales Volume by Application (2027-2032) & (K Doses) Table 45. Global Peptide Cancer Vaccine Sales Volume Share by Application (2021-2026) Table 46. Global Peptide Cancer Vaccine Sales Volume Share by Application (2027-2032) Table 47. Global Peptide Cancer Vaccine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Peptide Cancer Vaccine Sales Value by Application (2021-2026) & (US$ Million) Table 49. Global Peptide Cancer Vaccine Sales Value by Application (2027-2032) & (US$ Million) Table 50. Global Peptide Cancer Vaccine Sales Value Share by Application (2021-2026) Table 51. Global Peptide Cancer Vaccine Sales Value Share by Application (2027-2032) Table 52. Global Peptide Cancer Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Doses) Table 53. Global Peptide Cancer Vaccine Sales by Region (2021-2026) & (K Doses) Table 54. Global Peptide Cancer Vaccine Sales Market Share by Region (2021-2026) Table 55. Global Peptide Cancer Vaccine Sales by Region (2027-2032) & (K Doses) Table 56. Global Peptide Cancer Vaccine Sales Market Share by Region (2027-2032) Table 57. Global Peptide Cancer Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Peptide Cancer Vaccine Sales Value by Region (2021-2026) & (US$ Million) Table 59. Global Peptide Cancer Vaccine Sales Value Share by Region (2021-2026) Table 60. Global Peptide Cancer Vaccine Sales Value by Region (2027-2032) & (US$ Million) Table 61. Global Peptide Cancer Vaccine Sales Value Share by Region (2027-2032) Table 62. Global Peptide Cancer Vaccine Market Average Price (USD/Dose) by Region (2021-2026) Table 63. Global Peptide Cancer Vaccine Market Average Price (USD/Dose) by Region (2027-2032) Table 64. Global Peptide Cancer Vaccine Sales by Country: 2021 VS 2025 VS 2032 (K Doses) Table 65. Global Peptide Cancer Vaccine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 66. Global Peptide Cancer Vaccine Sales by Country (2021-2026) & (K Doses) Table 67. Global Peptide Cancer Vaccine Sales Market Share by Country (2021-2026) Table 68. Global Peptide Cancer Vaccine Sales by Country (2027-2032) & (K Doses) Table 69. Global Peptide Cancer Vaccine Sales Market Share by Country (2027-2032) Table 70. Global Peptide Cancer Vaccine Sales Value by Country (2021-2026) & (US$ Million) Table 71. Global Peptide Cancer Vaccine Sales Value Market Share by Country (2021-2026) Table 72. Global Peptide Cancer Vaccine Sales Value by Country (2027-2032) & (US$ Million) Table 73. Global Peptide Cancer Vaccine Sales Value Market Share by Country (2027-2032) Table 74. Boston Biomedical Company Information Table 75. Boston Biomedical Business Overview Table 76. Boston Biomedical Peptide Cancer Vaccine Sales (K Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 77. Boston Biomedical Peptide Cancer Vaccine Product Portfolio Table 78. Boston Biomedical Recent Development Table 79. Ultimovacs Company Information Table 80. Ultimovacs Business Overview Table 81. Ultimovacs Peptide Cancer Vaccine Sales (K Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 82. Ultimovacs Peptide Cancer Vaccine Product Portfolio Table 83. Ultimovacs Recent Development Table 84. BrightPath Biotherapeutics Company Information Table 85. BrightPath Biotherapeutics Business Overview Table 86. BrightPath Biotherapeutics Peptide Cancer Vaccine Sales (K Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 87. BrightPath Biotherapeutics Peptide Cancer Vaccine Product Portfolio Table 88. BrightPath Biotherapeutics Recent Development Table 89. TapImmune Company Information Table 90. TapImmune Business Overview Table 91. TapImmune Peptide Cancer Vaccine Sales (K Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 92. TapImmune Peptide Cancer Vaccine Product Portfolio Table 93. TapImmune Recent Development Table 94. Immatics Company Information Table 95. Immatics Business Overview Table 96. Immatics Peptide Cancer Vaccine Sales (K Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 97. Immatics Peptide Cancer Vaccine Product Portfolio Table 98. Immatics Recent Development Table 99. Sellas Company Information Table 100. Sellas Business Overview Table 101. Sellas Peptide Cancer Vaccine Sales (K Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 102. Sellas Peptide Cancer Vaccine Product Portfolio Table 103. Sellas Recent Development Table 104. Imugene Company Information Table 105. Imugene Business Overview Table 106. Imugene Peptide Cancer Vaccine Sales (K Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 107. Imugene Peptide Cancer Vaccine Product Portfolio Table 108. Imugene Recent Development Table 109. VAXON Biotech Company Information Table 110. VAXON Biotech Business Overview Table 111. VAXON Biotech Peptide Cancer Vaccine Sales (K Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 112. VAXON Biotech Peptide Cancer Vaccine Product Portfolio Table 113. VAXON Biotech Recent Development Table 114. Generex Biotechnology Company Information Table 115. Generex Biotechnology Business Overview Table 116. Generex Biotechnology Peptide Cancer Vaccine Sales (K Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 117. Generex Biotechnology Peptide Cancer Vaccine Product Portfolio Table 118. Generex Biotechnology Recent Development Table 119. ISA Pharmaceuticals Company Information Table 120. ISA Pharmaceuticals Business Overview Table 121. ISA Pharmaceuticals Peptide Cancer Vaccine Sales (K Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 122. ISA Pharmaceuticals Peptide Cancer Vaccine Product Portfolio Table 123. ISA Pharmaceuticals Recent Development Table 124. OncoTherapy Science Company Information Table 125. OncoTherapy Science Business Overview Table 126. OncoTherapy Science Peptide Cancer Vaccine Sales (K Doses), Value (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 127. OncoTherapy Science Peptide Cancer Vaccine Product Portfolio Table 128. OncoTherapy Science Recent Development Table 129. Key Raw Materials Table 130. Raw Materials Key Suppliers Table 131. Peptide Cancer Vaccine Distributors List Table 132. Peptide Cancer Vaccine Customers List Table 133. Research Programs/Design for This Report Table 134. Authors List of This Report Table 135. Secondary Sources Table 136. Primary Sources List of Figures Figure 1. Peptide Cancer Vaccine Product Image Figure 2. Global Peptide Cancer Vaccine Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Peptide Cancer Vaccine Sales Value (2021-2032) & (US$ Million) Figure 4. Global Peptide Cancer Vaccine Sales (2021-2032) & (K Doses) Figure 5. Global Peptide Cancer Vaccine Sales Average Price (USD/Dose) & (2021-2032) Figure 6. Global Peptide Cancer Vaccine Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. ITK-1 Image Figure 10. GRN-1201 Image Figure 11. TPIV200 Image Figure 12. TPIV110 Image Figure 13. UV1 Image Figure 14. Galinpepimut-S Image Figure 15. TARP 27-35 Image Figure 16. HER-Vaxx Image Figure 17. Vx-001 Image Figure 18. Others Image Figure 19. Global Peptide Cancer Vaccine Sales Volume by Type (2021 VS 2025 VS 2032) & (K Doses) Figure 20. Global Peptide Cancer Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Peptide Cancer Vaccine Sales Volume Share by Type (2021-2032) Figure 22. Global Peptide Cancer Vaccine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Peptide Cancer Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Peptide Cancer Vaccine Sales Value Share by Type (2021-2032) Figure 25. Breast Cancer Image Figure 26. Lung Cancer Image Figure 27. Melanoma Image Figure 28. Prostate Cancer Image Figure 29. Others Image Figure 30. Global Peptide Cancer Vaccine Sales Volume by Application (2021 VS 2025 VS 2032) & (K Doses) Figure 31. Global Peptide Cancer Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 32. Global Peptide Cancer Vaccine Sales Volume Share by Application (2021-2032) Figure 33. Global Peptide Cancer Vaccine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 34. Global Peptide Cancer Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 35. Global Peptide Cancer Vaccine Sales Value Share by Application (2021-2032) Figure 36. Global Peptide Cancer Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Doses) Figure 37. Global Peptide Cancer Vaccine Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 38. Global Peptide Cancer Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 39. Global Peptide Cancer Vaccine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 40. North America Peptide Cancer Vaccine Sales Value (2021-2032) & (US$ Million) Figure 41. North America Peptide Cancer Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 42. Europe Peptide Cancer Vaccine Sales Value (2021-2032) & (US$ Million) Figure 43. Europe Peptide Cancer Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 44. Asia-Pacific Peptide Cancer Vaccine Sales Value (2021-2032) & (US$ Million) Figure 45. Asia-Pacific Peptide Cancer Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 46. South America Peptide Cancer Vaccine Sales Value (2021-2032) & (US$ Million) Figure 47. South America Peptide Cancer Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 48. Middle East & Africa Peptide Cancer Vaccine Sales Value (2021-2032) & (US$ Million) Figure 49. Middle East & Africa Peptide Cancer Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 50. USA Peptide Cancer Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. USA Peptide Cancer Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. USA Peptide Cancer Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Canada Peptide Cancer Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Canada Peptide Cancer Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Canada Peptide Cancer Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Mexico Peptide Cancer Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Mexico Peptide Cancer Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Mexico Peptide Cancer Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Germany Peptide Cancer Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Germany Peptide Cancer Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Germany Peptide Cancer Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. France Peptide Cancer Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. France Peptide Cancer Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. France Peptide Cancer Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. U.K. Peptide Cancer Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. U.K. Peptide Cancer Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. U.K. Peptide Cancer Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Italy Peptide Cancer Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Italy Peptide Cancer Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Italy Peptide Cancer Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Spain Peptide Cancer Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Spain Peptide Cancer Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Spain Peptide Cancer Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Russia Peptide Cancer Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Russia Peptide Cancer Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Russia Peptide Cancer Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Netherlands Peptide Cancer Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Netherlands Peptide Cancer Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Netherlands Peptide Cancer Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Nordic Countries Peptide Cancer Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Nordic Countries Peptide Cancer Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Nordic Countries Peptide Cancer Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. China Peptide Cancer Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. China Peptide Cancer Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. China Peptide Cancer Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Japan Peptide Cancer Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Japan Peptide Cancer Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Japan Peptide Cancer Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. South Korea Peptide Cancer Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. South Korea Peptide Cancer Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. South Korea Peptide Cancer Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. India Peptide Cancer Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. India Peptide Cancer Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. India Peptide Cancer Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Australia Peptide Cancer Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Australia Peptide Cancer Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Australia Peptide Cancer Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Southeast Asia Peptide Cancer Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Southeast Asia Peptide Cancer Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Southeast Asia Peptide Cancer Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Brazil Peptide Cancer Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Brazil Peptide Cancer Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Brazil Peptide Cancer Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Argentina Peptide Cancer Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Argentina Peptide Cancer Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Argentina Peptide Cancer Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Chile Peptide Cancer Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Chile Peptide Cancer Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Chile Peptide Cancer Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Colombia Peptide Cancer Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Colombia Peptide Cancer Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Colombia Peptide Cancer Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Peru Peptide Cancer Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Peru Peptide Cancer Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Peru Peptide Cancer Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Saudi Arabia Peptide Cancer Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Saudi Arabia Peptide Cancer Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Saudi Arabia Peptide Cancer Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Israel Peptide Cancer Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Israel Arabia Peptide Cancer Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Israel Arabia Peptide Cancer Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. UAE Peptide Cancer Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. UAE Peptide Cancer Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. UAE Peptide Cancer Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Turkey Peptide Cancer Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 126. Turkey Peptide Cancer Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 127. Turkey Peptide Cancer Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 128. Iran Peptide Cancer Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 129. Iran Peptide Cancer Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 130. Iran Peptide Cancer Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 131. Egypt Peptide Cancer Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 132. Egypt Peptide Cancer Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 133. Egypt Peptide Cancer Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 134. Peptide Cancer Vaccine Value Chain Figure 135. Manufacturing Cost Structure Figure 136. Peptide Cancer Vaccine Sales Mode & Process Figure 137. Direct Comparison with Distribution Share Figure 138. Distributors Profiles Figure 139. Years Considered Figure 140. Research Process Figure 141. Key Executives Interviewed

Scope & coverage.

Types
  • ITK-1
  • GRN-1201
  • TPIV200
  • TPIV110
  • UV1
  • Galinpepimut-S
  • TARP 27-35
  • HER-Vaxx
  • Vx-001
  • Others
Applications
  • Breast Cancer
  • Lung Cancer
  • Melanoma
  • Prostate Cancer
  • Others
Companies covered
  • Boston Biomedical
  • Ultimovacs
  • BrightPath Biotherapeutics
  • TapImmune
  • Immatics
  • Sellas
  • Imugene
  • VAXON Biotech
  • Generex Biotechnology
  • ISA Pharmaceuticals
  • OncoTherapy Science

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Peptide Cancer Vaccine Sales Value (2021-2032)
  4. 1.2.2 Global Peptide Cancer Vaccine Sales Volume (2021-2032)
  5. 1.2.3 Global Peptide Cancer Vaccine Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Peptide Cancer Vaccine Market Dynamics
  1. 2.1 Peptide Cancer Vaccine Industry Trends
  2. 2.2 Peptide Cancer Vaccine Industry Drivers
  3. 2.3 Peptide Cancer Vaccine Industry Opportunities and Challenges
  4. 2.4 Peptide Cancer Vaccine Industry Restraints
3 Peptide Cancer Vaccine Market by Company
  1. 3.1 Global Peptide Cancer Vaccine Company Revenue Ranking in 2025
  2. 3.2 Global Peptide Cancer Vaccine Revenue by Company (2021-2026)
  3. 3.3 Global Peptide Cancer Vaccine Sales Volume by Company (2021-2026)
  4. 3.4 Global Peptide Cancer Vaccine Average Price by Company (2021-2026)
  5. 3.5 Global Peptide Cancer Vaccine Company Ranking (2024-2026)
  6. 3.6 Global Peptide Cancer Vaccine Company Manufacturing Base and Headquarters
  7. 3.7 Global Peptide Cancer Vaccine Company Product Type and Application
  8. 3.8 Global Peptide Cancer Vaccine Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Peptide Cancer Vaccine Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Peptide Cancer Vaccine Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Peptide Cancer Vaccine Market by Type
  1. 4.1 Peptide Cancer Vaccine Type Introduction
  2. 4.1.1 ITK-1
  3. 4.1.2 GRN-1201
  4. 4.1.3 TPIV200
  5. 4.1.4 TPIV110
  6. 4.1.5 UV1
  7. 4.1.6 Galinpepimut-S
  8. 4.1.7 TARP 27-35
  9. 4.1.8 HER-Vaxx
  10. 4.1.9 Vx-001
  11. 4.1.10 Others
  12. 4.2 Global Peptide Cancer Vaccine Sales Volume by Type
  13. 4.2.1 Global Peptide Cancer Vaccine Sales Volume by Type (2021 VS 2025 VS 2032)
  14. 4.2.2 Global Peptide Cancer Vaccine Sales Volume by Type (2021-2032)
  15. 4.2.3 Global Peptide Cancer Vaccine Sales Volume Share by Type (2021-2032)
  16. 4.3 Global Peptide Cancer Vaccine Sales Value by Type
  17. 4.3.1 Global Peptide Cancer Vaccine Sales Value by Type (2021 VS 2025 VS 2032)
  18. 4.3.2 Global Peptide Cancer Vaccine Sales Value by Type (2021-2032)
  19. 4.3.3 Global Peptide Cancer Vaccine Sales Value Share by Type (2021-2032)
5 Peptide Cancer Vaccine Market by Application
  1. 5.1 Peptide Cancer Vaccine Application Introduction
  2. 5.1.1 Breast Cancer
  3. 5.1.2 Lung Cancer
  4. 5.1.3 Melanoma
  5. 5.1.4 Prostate Cancer
  6. 5.1.5 Others
  7. 5.2 Global Peptide Cancer Vaccine Sales Volume by Application
  8. 5.2.1 Global Peptide Cancer Vaccine Sales Volume by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Peptide Cancer Vaccine Sales Volume by Application (2021-2032)
  10. 5.2.3 Global Peptide Cancer Vaccine Sales Volume Share by Application (2021-2032)
  11. 5.3 Global Peptide Cancer Vaccine Sales Value by Application
  12. 5.3.1 Global Peptide Cancer Vaccine Sales Value by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global Peptide Cancer Vaccine Sales Value by Application (2021-2032)
  14. 5.3.3 Global Peptide Cancer Vaccine Sales Value Share by Application (2021-2032)
6 Peptide Cancer Vaccine Regional Sales and Value Analysis
  1. 6.1 Global Peptide Cancer Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Peptide Cancer Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Peptide Cancer Vaccine Sales by Region: 2021-2026
  4. 6.2.2 Global Peptide Cancer Vaccine Sales by Region (2027-2032)
  5. 6.3 Global Peptide Cancer Vaccine Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Peptide Cancer Vaccine Sales Value by Region (2021-2032)
  7. 6.4.1 Global Peptide Cancer Vaccine Sales Value by Region: 2021-2026
  8. 6.4.2 Global Peptide Cancer Vaccine Sales Value by Region (2027-2032)
  9. 6.5 Global Peptide Cancer Vaccine Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Peptide Cancer Vaccine Sales Value (2021-2032)
  12. 6.6.2 North America Peptide Cancer Vaccine Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Peptide Cancer Vaccine Sales Value (2021-2032)
  15. 6.7.2 Europe Peptide Cancer Vaccine Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Peptide Cancer Vaccine Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Peptide Cancer Vaccine Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Peptide Cancer Vaccine Sales Value (2021-2032)
  21. 6.9.2 South America Peptide Cancer Vaccine Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Peptide Cancer Vaccine Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Peptide Cancer Vaccine Sales Value Share by Country, 2025 VS 2032
7 Peptide Cancer Vaccine Country-level Sales and Value Analysis
  1. 7.1 Global Peptide Cancer Vaccine Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Peptide Cancer Vaccine Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Peptide Cancer Vaccine Sales by Country (2021-2032)
  4. 7.3.1 Global Peptide Cancer Vaccine Sales by Country (2021-2026)
  5. 7.3.2 Global Peptide Cancer Vaccine Sales by Country (2027-2032)
  6. 7.4 Global Peptide Cancer Vaccine Sales Value by Country (2021-2032)
  7. 7.4.1 Global Peptide Cancer Vaccine Sales Value by Country (2021-2026)
  8. 7.4.2 Global Peptide Cancer Vaccine Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Peptide Cancer Vaccine Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Peptide Cancer Vaccine Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Peptide Cancer Vaccine Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Peptide Cancer Vaccine Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Peptide Cancer Vaccine Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Peptide Cancer Vaccine Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Peptide Cancer Vaccine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Peptide Cancer Vaccine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Peptide Cancer Vaccine Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Peptide Cancer Vaccine Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Peptide Cancer Vaccine Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Peptide Cancer Vaccine Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Peptide Cancer Vaccine Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Peptide Cancer Vaccine Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Peptide Cancer Vaccine Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Peptide Cancer Vaccine Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Peptide Cancer Vaccine Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Peptide Cancer Vaccine Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Peptide Cancer Vaccine Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Peptide Cancer Vaccine Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Peptide Cancer Vaccine Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Peptide Cancer Vaccine Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Peptide Cancer Vaccine Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Peptide Cancer Vaccine Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Peptide Cancer Vaccine Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Peptide Cancer Vaccine Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Peptide Cancer Vaccine Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Peptide Cancer Vaccine Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Peptide Cancer Vaccine Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Peptide Cancer Vaccine Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Peptide Cancer Vaccine Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Peptide Cancer Vaccine Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Peptide Cancer Vaccine Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Peptide Cancer Vaccine Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Peptide Cancer Vaccine Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Peptide Cancer Vaccine Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Peptide Cancer Vaccine Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Peptide Cancer Vaccine Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Peptide Cancer Vaccine Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Peptide Cancer Vaccine Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Peptide Cancer Vaccine Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Peptide Cancer Vaccine Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Peptide Cancer Vaccine Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Peptide Cancer Vaccine Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Peptide Cancer Vaccine Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Peptide Cancer Vaccine Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Peptide Cancer Vaccine Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Peptide Cancer Vaccine Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Peptide Cancer Vaccine Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Peptide Cancer Vaccine Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Peptide Cancer Vaccine Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Peptide Cancer Vaccine Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Peptide Cancer Vaccine Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Peptide Cancer Vaccine Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Peptide Cancer Vaccine Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Peptide Cancer Vaccine Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Peptide Cancer Vaccine Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Peptide Cancer Vaccine Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Peptide Cancer Vaccine Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Peptide Cancer Vaccine Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Peptide Cancer Vaccine Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Peptide Cancer Vaccine Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Peptide Cancer Vaccine Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Peptide Cancer Vaccine Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Peptide Cancer Vaccine Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Peptide Cancer Vaccine Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Peptide Cancer Vaccine Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Peptide Cancer Vaccine Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Peptide Cancer Vaccine Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Peptide Cancer Vaccine Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Peptide Cancer Vaccine Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Peptide Cancer Vaccine Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Peptide Cancer Vaccine Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Peptide Cancer Vaccine Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Peptide Cancer Vaccine Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Peptide Cancer Vaccine Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Peptide Cancer Vaccine Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Peptide Cancer Vaccine Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Peptide Cancer Vaccine Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Peptide Cancer Vaccine Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Peptide Cancer Vaccine Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Peptide Cancer Vaccine Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Peptide Cancer Vaccine Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Peptide Cancer Vaccine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Boston Biomedical
  2. 8.1.1 Boston Biomedical Company Information
  3. 8.1.2 Boston Biomedical Business Overview
  4. 8.1.3 Boston Biomedical Peptide Cancer Vaccine Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Boston Biomedical Peptide Cancer Vaccine Product Portfolio
  6. 8.1.5 Boston Biomedical Recent Developments
  7. 8.2 Ultimovacs
  8. 8.2.1 Ultimovacs Company Information
  9. 8.2.2 Ultimovacs Business Overview
  10. 8.2.3 Ultimovacs Peptide Cancer Vaccine Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Ultimovacs Peptide Cancer Vaccine Product Portfolio
  12. 8.2.5 Ultimovacs Recent Developments
  13. 8.3 BrightPath Biotherapeutics
  14. 8.3.1 BrightPath Biotherapeutics Company Information
  15. 8.3.2 BrightPath Biotherapeutics Business Overview
  16. 8.3.3 BrightPath Biotherapeutics Peptide Cancer Vaccine Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 BrightPath Biotherapeutics Peptide Cancer Vaccine Product Portfolio
  18. 8.3.5 BrightPath Biotherapeutics Recent Developments
  19. 8.4 TapImmune
  20. 8.4.1 TapImmune Company Information
  21. 8.4.2 TapImmune Business Overview
  22. 8.4.3 TapImmune Peptide Cancer Vaccine Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 TapImmune Peptide Cancer Vaccine Product Portfolio
  24. 8.4.5 TapImmune Recent Developments
  25. 8.5 Immatics
  26. 8.5.1 Immatics Company Information
  27. 8.5.2 Immatics Business Overview
  28. 8.5.3 Immatics Peptide Cancer Vaccine Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Immatics Peptide Cancer Vaccine Product Portfolio
  30. 8.5.5 Immatics Recent Developments
  31. 8.6 Sellas
  32. 8.6.1 Sellas Company Information
  33. 8.6.2 Sellas Business Overview
  34. 8.6.3 Sellas Peptide Cancer Vaccine Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Sellas Peptide Cancer Vaccine Product Portfolio
  36. 8.6.5 Sellas Recent Developments
  37. 8.7 Imugene
  38. 8.7.1 Imugene Company Information
  39. 8.7.2 Imugene Business Overview
  40. 8.7.3 Imugene Peptide Cancer Vaccine Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Imugene Peptide Cancer Vaccine Product Portfolio
  42. 8.7.5 Imugene Recent Developments
  43. 8.8 VAXON Biotech
  44. 8.8.1 VAXON Biotech Company Information
  45. 8.8.2 VAXON Biotech Business Overview
  46. 8.8.3 VAXON Biotech Peptide Cancer Vaccine Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 VAXON Biotech Peptide Cancer Vaccine Product Portfolio
  48. 8.8.5 VAXON Biotech Recent Developments
  49. 8.9 Generex Biotechnology
  50. 8.9.1 Generex Biotechnology Company Information
  51. 8.9.2 Generex Biotechnology Business Overview
  52. 8.9.3 Generex Biotechnology Peptide Cancer Vaccine Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Generex Biotechnology Peptide Cancer Vaccine Product Portfolio
  54. 8.9.5 Generex Biotechnology Recent Developments
  55. 8.10 ISA Pharmaceuticals
  56. 8.10.1 ISA Pharmaceuticals Company Information
  57. 8.10.2 ISA Pharmaceuticals Business Overview
  58. 8.10.3 ISA Pharmaceuticals Peptide Cancer Vaccine Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 ISA Pharmaceuticals Peptide Cancer Vaccine Product Portfolio
  60. 8.10.5 ISA Pharmaceuticals Recent Developments
  61. 8.11 OncoTherapy Science
  62. 8.11.1 OncoTherapy Science Company Information
  63. 8.11.2 OncoTherapy Science Business Overview
  64. 8.11.3 OncoTherapy Science Peptide Cancer Vaccine Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 OncoTherapy Science Peptide Cancer Vaccine Product Portfolio
  66. 8.11.5 OncoTherapy Science Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Peptide Cancer Vaccine Value Chain Analysis
  2. 9.1.1 Peptide Cancer Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Peptide Cancer Vaccine Sales Mode & Process
  6. 9.2 Peptide Cancer Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Peptide Cancer Vaccine Distributors
  9. 9.2.3 Peptide Cancer Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst